KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Intangibles: 2009-2024

Historic Amortization - Intangibles for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $43.3 million.

  • Biomarin Pharmaceutical's Amortization - Intangibles fell 3.23% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 50.47%. This contributed to the annual value of $43.3 million for FY2024, which is 30.47% down from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Amortization - Intangibles is $43.3 million, which was down 30.47% from $62.2 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Amortization - Intangibles registered a high of $69.9 million during FY2021, and its lowest value of $43.3 million during FY2024.
  • In the last 3 years, Biomarin Pharmaceutical's Amortization - Intangibles had a median value of $62.2 million in 2023 and averaged $57.6 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Amortization - Intangibles increased by 4.91% in 2021, and later tumbled by 30.47% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Amortization - Intangibles stood at $66.7 million in 2020, then climbed by 4.91% to $69.9 million in 2021, then dropped by 3.92% to $67.2 million in 2022, then decreased by 7.41% to $62.2 million in 2023, then plummeted by 30.47% to $43.3 million in 2024.